Purpose: This study attempted to develop a method to measure the applied recursive filtration and to determine the noise reduction of four different fluoroscopic systems. The study also attempted to elucidate the importance of considering the recursive filter for quality control tests concerning signal-to-noise ratio (SNR) or image quality. The vendor's settings for recursive filtration factor (β) are, unfortunately, often not available. Hence, a method to determine the recursive filtration and associated noise reduction would be useful.
Method: The recursive filter was determined by using a single fluoroscopic series and the method presented in this study. The theoretical noise reduction based on the choice of β was presented. In addition, the corresponding noise reduction, evaluated as the ratio of the standard deviation of the pixel value between a series with β equal to zero (recursive filtration off) and β > 0, was determined for different pulse rates given by pulses per second (pps), doses (mAs) and recursive filter. The images were acquired using clinically relevant radiation quality and quantity.
Results: The presented method to measure the recursive filter exhibited high accuracy (1.08%) and precision (1.48%). The recursive filtration and noise reduction were measured for several settings for each vendor. The recursive filtration settings and associated recursive filtration factors for four different vendors were presented.
Conclusions: This study presented an accurate method to determine applied recursive filtration, which was easy to determine. Hence, for all quality control purposes, including noise evaluation, it was possible to consider the essential noise reduction given by the settings for recursive filtration. It was also possible to compare the recursive filtration settings and associated recursive filtration within and between vendors.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856489 | PMC |
http://dx.doi.org/10.1002/acm2.13115 | DOI Listing |
Diabetes Obes Metab
December 2024
Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Aims: The ACCORD trial showed that intensive glucose-lowering therapy has a limited impact on renal function decline. We aimed to identify subgroups in the ACCORD population that might derive renal benefits from intensive glucose-lowering therapy.
Materials And Methods: The primary renal outcome included a ≥50% decline in baseline estimated glomerular filtration rate or end-stage renal disease (ESRD).
Sensors (Basel)
June 2024
Research Institute for Intelligent Computer Systems, West Ukrainian National University, 11 Lvivska Street, 46009 Ternopil, Ukraine.
The article's main provisions are the development and application of a neural network method for helicopter turboshaft engine thermogas-dynamic parameter integrating signals. This allows you to effectively correct sensor data in real time, ensuring high accuracy and reliability of readings. A neural network has been developed that integrates closed loops for the helicopter turboshaft engine parameters, which are regulated based on the filtering method.
View Article and Find Full Text PDFMed Clin (Barc)
August 2024
Departamento de Estadística, Matemáticas e Informática, Instituto Universitario Centro de Investigación Operativa (CIO), Universidad Miguel Hernández, Elche, Alicante, España.
Background: Coronary heart disease is the leading cause of heart failure (HF), and tools are needed to identify patients with a higher probability of developing HF after an acute coronary syndrome (ACS). Artificial intelligence (AI) has proven to be useful in identifying variables related to the development of cardiovascular complications.
Methods: We included all consecutive patients discharged after ACS in two Spanish centers between 2006 and 2017.
Age Ageing
May 2024
Institute of Geriatric Research, Ulm University Medical Center, Ulm, Germany.
Eur J Heart Fail
January 2024
Department of Physiology, Anatomy and Genetics, British Heart Foundation Centre of Excellence, University of Oxford, Oxford, UK.
Aims: Neuropeptide Y (NPY) is the most abundant neuropeptide found in the heart and is released alongside norepinephrine following prolonged sympathetic activation, a process that is implicated in the pathophysiology of heart failure (HF). In patients with severely impaired left ventricular ejection fraction (LVEF) undergoing cardiac resynchronization therapy, higher levels of NPY measured in coronary sinus blood, are associated with poorer outcome. The aim was to examine the association of peripheral venous NPY levels and outcomes in a HF population with a range of LVEF, using a highly sensitive and specific assay.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!